Matthew Linden is an Associate Professor in Pathology and Laboratory Science in the School of Biomedical Sciences at The University of Western Australia (Perth). His research develops enabling cytometric and molecular tools to measure platelet phenotype, function, and interactions. He applies these approaches to translate platelet biology into reproducible biomarkers for diagnosis, prognostication, disease monitoring, as well as the development and evaluation of platelet-targeting therapies in clinical trials, with interests including myeloproliferative neoplasms, haematological malignancy, trauma, and cardiovascular disease. He contributes to best-practice guidelines and industry translation through collaborations, commercial partnerships, and intellectual property. He leads accredited, work-integrated postgraduate training in haematology and transfusion science. Matthew serves on the Board of Trustees of the International Society for the Advancement of Cytometry, is Councilor and Past President of the Australasian Cytometry Society, and co-convener of CYTO-Connect Perth.

Dr. Sa Wang is a Professor of Pathology, Section Chief of Flow Cytometry, and Deputy Chair in the Department of Hematopathology at The University of Texas MD Anderson Cancer Center. Her clinical and research expertise focus on hematolymphoid neoplasms, integrating histopathology, flow cytometry, and molecular genetics for diagnosis, classification, and risk stratification. Dr. Wang has authored over 350 peer-reviewed original research articles and case reports, as well as 36 review articles and 31 book chapters across 12 reference books. She is co-editor of Diagnosis of Blood and Bone Marrow Disorders and the 4th edition of Hematopathology in the Foundations in Diagnostic Pathology series. She serves as Associate Editor of Cytometry B: Clinical Cytometry and is Past President of the International Clinical Cytometry Society (ICCS). An active educator and international speaker, Dr. Wang directs and contributes to numerous CME courses and professional meetings. She has participated in national and international guideline development for acute leukemia diagnosis and AML MRD monitoring and is an active member of the European LeukemiaNet (ELN) AML MRD and MDS Flow Cytometry working groups, with ongoing industry-supported research in tumor biomarker development.

TJ Beadnell has 10 years of flow cytometry experience with 5 of those years spent in clinical flow cytometry.  His graduate work at the University of Colorado Anschutz Medical Campus focused on resistance mechanisms to targeted therapeutics followed by his postdoctoral work at the University of Kansas Cancer Center which focused on defining the role of mitochondrial genetics in regulating immune cell development and function and the impact on cancer cell metastasis. He then joined Eurofins Clinical Trial Solutions as a research scientist to help support their live cell capabilities. As a scientist he helped establish Eurofins Clinical Trial Solutions first high parameter (26-marker) flow cytometry panel.  He then transitioned into managing the Flow Cytometry team and has overseen the training of multiple associates and the development and validation of flow cytometry assays to support clinical trials. He currently advises on global live cell capabilities with an emphasis on Flow Cytometry, ELISPOT, and PBMC Processing, supporting Eurofins Clinical Trial Solutions’ global flow cytometry labs located across the US, Europe, Singapore, and China.  His current role and efforts are dedicated to harmonization and quality standardization of live cell technologies.  He is a member of the International Society for Advancement of Cytometry (ISAC) and the International Clinical Cytometry Society (ICCS).

Virginia Litwin is a thought-leader in validation and standardization focusing on “Cytometry from Bench-to-Bedside”. Virginia is President-Elect of ISAC and in 2023 she received the ICCS Coulter award in recognition of contributions to Clinical Cytometry. She is a member of the NIST Flow Cytometry Standards Consortium and has been an invited speaker at FDA/NIST several times. Virginia serves on the CLSI Expert Panel and is chair for H62 and H42. She is an Editor for Cytometry Part B and has been a guest editor for special issues addressing translational cytometry. She founded the AAPS Flow Cytometry Community. After obtaining a Ph.D. in Virology/Immunology from the University of Iowa, Virginia joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified the KIR receptor, CD158E1. She has held leadership roles in several contract research organizations. Currently she is Scientific Affairs Director at Eurofins Clinical Trial Solutions.

Daniel T. Chiu is the A. Bruce Montgomery Professor of Chemistry and Endowed Professor of Analytical Chemistry, and Professor of Bioengineering at the University of Washington. He is a member of the Cancer Consortium at the Fred Hutchinson Cancer Research Center. His research interests include nanomaterials, microfluidics, and new instrumentations for ultra-sensitive bioanalytical measurements. He obtained a B.A. in Neurobiology and a B.S. in Chemistry from UC Berkeley in 1993, then a Ph.D. in Chemistry from Stanford University in 1998. After completing postdoctoral research at Harvard University, he started in 2000 at the University of Washington. He is the author of more than 250 publications and is the inventor on over 300 issued patents.

Abraham (Abe) P. Lee is Chancellor’s Professor of Biomedical Engineering (BME), Pharm Sci and MAE at the University of California, Irvine (UCI). He served as department chair for BME from 2010-2019. He is Director of the “Center for Advanced Design & Manufacturing of Integrated Microfluidics” (CADMIM). Dr. Lee previously served as Editor-in-Chief for the Lab on a Chip journal (2017-2020). Prior to UCI, he worked for the National Cancer Institute (NCI), and was a Program Manager at DARPA. Dr. Lee’s current research focuses on microfluidic systems for precision medicine including liquid biopsy, microphysiological systems, cell engineering, and immunotherapy. He is inventor of over 60 issued US patents and is author of over 130 journals articles. Professor Lee was awarded the 2009 Pioneers of Miniaturization Prize and is fellow of the National Academy of Inventors (NAI), Biomedical Engineering Society (BMES) and several other professional societies (AIMBE, RSC, ASME, and the IAMBE.

David Klenerman is a physical chemist who graduated and completed his doctorate at Cambridge University working with Professor Ian Smith on infra-red chemiluminescence for his PhD in 1985. This was followed by postdoctoral research at Stanford University, California with Professor Dick Zare on high overtone chemistry. He then returned to the U.K. and worked for seven years for BP Research in their Laser Spectroscopy Group before returning to the Department of Chemistry, University of Cambridge, progressing to a Professorship. He is currently a Royal Society GSK Professor of Molecular Medicine. At Cambridge his work has focussed on the development and application of physical methods, particularly laser spectroscopy and single molecule fluorescence, to biological and biomedical problems. He is best known for co-inventing  next-generation sequencing of DNA .Klenerman is a Fellow of the Royal Society, Academy of Medical Science  and Academia Europaea and  was knighted in 2018. He was awarded the 2020 Millennium Technology Prize and 2024 Novo Nordisk prize jointly with Shankar Balasubramanian and the 2022 Breakthrough Prize for Life Sciences and 2024 Canada Gairdner International award jointly with Shankar Balasubramanian and Pascal Mayer for next generation DNA sequencing.

Pietro Ferraro is a Research Director at the National Research Council of Italy (CNR). He previously served as the Director of the Institute of Applied Sciences and Intelligent Systems (ISASI) and President of the CNR Research Area in Pozzuoli from 2012 to 2019. He is a physicist, his career spans leadership roles in both industry and public research. His research expertise includes digital holography, microscopy, and label-free 3D imaging for biomedical applications. A Fellow of both Optica and SPIE, Ferraro was awarded the prestigious SPIE Dennis Gabor Award in 2020 for his contributions to diffractive optics. He has authored over 380 journal papers, holding 14 patents.

Graduated in Physics from Queen Mary College, University of London, and earned a PhD at Lancaster University on Langmuir-Blodgett superlattices of porphyrins. After postdoctoral research at Imperial College London and a period as Visiting Scientist at Eastman Kodak, Rochester, NY, I joined the University of Leeds in 1991, becoming Professor of Molecular and Nanoscale Physics in 2002. Twice Head of School, currently serve on numerous advisory boards, including at Cambridge University and Imperial. His research focuses on advanced nanomaterials and biophysical technologies for healthcare, including the development of 2D gold-based nanoenzymes for catalytic therapies, microfluidic platforms for high-throughput production of therapeutic particles, and disease models to understand cancer progression. He also develops single-cell analysis using Raman spectroscopy and deformation cytometry to identify biochemical and mechanical markers of disease. This work aims to deliver innovative diagnostic and therapeutic strategies for early cancer detection and precision medicine.

Graduated in Physics from Queen Mary College, University of London, and earned a PhD at Lancaster University on Langmuir-Blodgett superlattices of porphyrins. After postdoctoral research at Imperial College London and a period as Visiting Scientist at Eastman Kodak, Rochester, NY, I joined the University of Leeds in 1991, becoming Professor of Molecular and Nanoscale Physics in 2002. Twice Head of School, currently serve on numerous advisory boards, including at Cambridge University and Imperial. His research focuses on advanced nanomaterials and biophysical technologies for healthcare, including the development of 2D gold-based nanoenzymes for catalytic therapies, microfluidic platforms for high-throughput production of therapeutic particles, and disease models to understand cancer progression. He also develops single-cell analysis using Raman spectroscopy and deformation cytometry to identify biochemical and mechanical markers of disease. This work aims to deliver innovative diagnostic and therapeutic strategies for early cancer detection and precision medicine.

Melissa Skala is the Carol Skornicka Chair at the Morgridge Institute for Research and a Professor of Biomedical Engineering and Medical Physics at the University of Wisconsin - Madison. She is a fellow of the Professional Society for Optics and Photonics Technology (SPIE), Optica, and the American Institute for Medical and Biological Engineering (AIMBE). Her lab develops biomedical optical imaging technologies for cancer research, cell therapy, and immunology with support from the National Institutes of Health and the National Science Foundation. She serves as an editorial board member at Cancer Research and the Journal of Biomedical Optics, and is a member of the Advisory Committee for the Burroughs Wellcome Fund. Her inventions are undergoing commercialization through small business grants. She received her BS from Washington State University, MS from the University of Wisconsin – Madison, and PhD from Duke University.

Dr. Stephanie Xie is an Allan Slaight Scientist at the Princess Margaret Cancer Centre in the University Health Network and Assistant Professor in the Department of Medical Biophysics at the University of Toronto. Dr. Xie completed her Ph.D. at the Massachusetts of Technology and went onto postdoctoral fellowships at the Massachusetts General Hospital and Princess Margaret Cancer Centre. The Xie lab is focused on interrogating the mechanistic underpinnings of inflammatory and metabolic stress regulation in human hematopoietic and leukemia stem cells. Her work has provided fundamental insights into lipid regulation and inflammatory memory in the human stem cell setting. By understanding how stress promotes unhealthy aging and cancer, the goal is to discover novel cancer prevention and treatment strategies. She has been recognized for her work by the American Association of Cancer Research as a 2025 NextGen Star.

Professor, New Mexico State University

Keisuke Goda is currently a professor in the Department of Chemistry at the University of Tokyo, a distinguished professor in the SiRIUS Institute of Medical Research at Tohoku University, as well as an adjunct professor in the Department of Bioengineering at UCLA and the Institute of Technological Sciences at Wuhan University. He earned a B.A. degree summa cum laude in Physics from UC Berkeley in 2001 and a Ph.D. in Physics from MIT in 2007. His research group is currently dedicated to developing "serendipity-enabling biotechnologies" through extreme engineering. He has authored over 300 journal papers, filed over 30 patents, and launched 4 startups. Goda has received more than 30 awards and honors, including the Japan Academy Medal, JSPS Prize, SPIE Biophotonics Technology Innovator Award, and Philipp Franz von Siebold Award.

Nithianandan Selliah more than 30 years of Flow cytometry experience, including more than 10 years in clinical Flow cytometry. Flow cytometry experience started at National Jewish Medical center and then at Children’s Hospital of Philadelphia where he worked on HIV research in studying mechanism of CD4+ T cell apoptosis. Then he joined Roger Williams Medical Center to investigated CAR T-cells for HIV therapy. He utilized Flow cytometry in autoimmune disease research to identify potential biomarkers for lupus disease at a biotech company. Dr. Selliah joined Celgene to work on a specific project to explore therapeutic potential of red blood cells derived from in vitro differentiation of HSCs. Dr. Selliah’s clinical flow cytometry experience expanded at LabCorp drug development (formerly Covance) where he to helped with the expansion of flow cytometry supporting clinical drug development. He developed and validated more than 10 flow cytometric methods which were deployed in numerous global clinical trials. Currently, Dr. Selliah is the Global Director for Flow cytometry, where he lead a team of 12 scientists globally, overseeing development and validation of assays for global clinical trials. He presented at the International Clinical Cytometry Society (ICCS) meeting and the International Society for the Advancement of Cytometry’s (ISAC) annual meeting, CYTO. He also contributed to recommendation papers in Cytometry B and Current Protocols in Cytometry, and a chapter on receptor occupancy assays. Dr. Selliah presented a Webinar with Dr. Virginia Litwin on CLSI H62 guidelines.

Katharine Schwedhelm has over 15 years of flow cytometry experience, initially gaining experience in flow and instrumentation at Benaroya Research Institute before moving to Fred Hutchinson Cancer Center to join the HIV Vaccine Trials Network (HVTN) Endpoints laboratory. At the HVTN, as laboratory research manager, much of her focus has been directed to towards high parameter panel development to support HIV, TB, malaria, and COVID-19 vaccine studies and cytometer characterization and standardization. Katharine also supports the Cape Town HVTN laboratory, facilitating panel transfers and ensuring cross-lab assay and instrument concordance. She has been a returning instructor at the African Flow Cytometry Workshop, presented multiple times at the International Society for the Advancement of Cytometry’s (ISAC) annual meeting, CYTO, presented a webinar on the HVTN’s approach to instrument characterization and standardization for CYTO University, and contributed to a chapter for the newest edition of Flow Cytometry in Drug Discovery and Development.

John Nolan is Professor at the Scintillon Institute, where his group develops new instrumentation, reagents, and assays for cytometry and single cell analysis. He is also the founder of Cellarcus Biosciences, which provides tools and services for extracellular vesicle research and application. He earned BS degrees (Biology and Chemistry) at the University of Illinois, and a PhD (Biochemistry) from Penn State. He has served as Director of the National Flow Cytometry Resource at Los Alamos National Lab, President of the International Society for Advancement of Cytometry, and serves on the editorial board of Cytometry. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE).

Yuval Kluger has been working in the broad fields of bioinformatics, machine learning, and dynamics of quantum fields. His main contributions to date relate to development of spectral methods and machine learning methods for unsupervised and supervised learning, cell specific regulatory networks, algorithms for analyzing genomics and epigenomics sequencing data, and algorithms for detecting and characterizing biomarkers in high dimensional assays.

Garrett is a Scientist in the Cell Therapy Analytical Development group at Bristol Myers Squibb, where he and his group support the implementation of analytical tools to support cell therapy product development and characterization. Garrett has supported characterization activities for a wide variety of BMS cell therapies, including commercial products Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), as well as BMS's clinical phase products including GPRC5D, Dual Targeting BCMAxGPRC5D, and NEXT CD19 assets. In particular, Garrett focuses on implementing spectral cytometry to support the development of next-generation cell therapies. In his spare time, you can find Garrett cycling around Seattle's beautiful Burke Gilman trail or hosting dinner parties for his friends.

Rachael Walker has 25 years of cytometry experience, including over 20 years’ experience of running core facilities in Cambridge, UK. Rachael was first introduced to flow cytometry and cell sorting during her PhD in Clinical Engineering, University of Liverpool and decided to pursue a career in Flow Cytometry. She managed flow cytometry facilities at the University of Cambridge for 7 years before joining Babraham Institute as Head of Flow Cytometry in 2012. It is there that she has grown her facility from a 2-person 4 instrument core to a 5 person19 instrument which not only serves the Babraham Institute scientists but over 45 biotech companies. Rachael is actively involved with the flow cytometry community as Chair of the Cambridge Cytometry Club, Council member of the Royal Microscopical Society and Council member of ISAC (2022-2026).  Rachael became an ISAC scholar in 2012-2014 and transferred to the new Shared Resource Laboratory Emerging Leader program in 2014-2016.  Rachael remains actively involved with the ISAC Leadership Development Committee of which she is the council liaison member.  

Derek Davies has over 45 years of cytometry experience. Much of that time has been spend running large core facilities in the UK firstly at the London Research Institute and then at the Francis Crick Institute where he oversaw 30 cytometers and 12 staff. Over the years he has trained several thousand researchers in flow cytometry. In 2018 he was appointed to a newly created position as Training Lead in all Science Technology Platforms at the Francis Crick Institute where he developed a series of in-person, virtual and eLearning trainings. For the past 12 years he and Rachael Walker have delivered in person classroom and practical training at the Babraham Institute in Cambridge. He is now semi-retired but is still active in teaching and training. Derek is a former ISAC councillor and received the Society’s Membership Award in 2019. He has served on the Council of the Royal Microscopical Society, Chaired the Cytometry Section and was awarded the Presidential Medal in 2022.  

Joe Gray is Professor Emeritus in the Biomedical Engineering Department at OHSU and Laboratory Medicine at UCSF. His laboratory has developed advanced cellular, genome, and image analysis technologies to advance prenatal diagnosis, and radiation dosimetry, elucidate mechanisms involved in cancer genesis, progression, and response to therapy, and to develop more durable and tolerable cancer treatments. His work is described in over 570 publications and 150 US patents. He is a Fellow of the AAAS, the AIMBE, the AACR Academy, and a National Academy of Medicine member. Awards include the Research Award (RRS), the E.O. Lawrence Award (USDOE), Fulwyler Award (ISAC), Curt Stern Award (ASHG), Brinker Award (Susan G. Komen Foundation), Shubitz Award (University of Chicago), Knudson Award (NCI), three Team Science awards (AACR) and the Sinclair Medal (NCRPM).

Lewis L. Lanier is an American Cancer Society Professor and J. Michael Bishop MD Distinguished Professor Emeritus at University of California San Francisco and Founding Director of the Parker Institute for Immunotherapy at UCSF. Dr. Lanier received his B.S. in Biology from Virginia Tech and Ph.D. in Microbiology and Immunology from UNC - Chapel Hill. After postdoctoral studies, he joined the R&D Department at the Becton Dickinson Monoclonal Center, advancing to Associate Director. In 1990, he joined the DNAX Research Institute, where he advanced to Director of Immunobiology, and in 1999 joined the faculty of UCSF. His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses. In recognition of his contributions he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute (2002), received the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics (2005), was elected to the US National Academy of Sciences (2010), and the American Academy of Arts and Sciences (2011). He served as President of the American Association of Immunologists (2006-2007), received the AAI Excellence in Mentoring Award in 2017, and awarded the AAI Lifetime Achievement Award in 2023.

Dr. Paula Araya earned her Ph.D. in Immunology from Universidad Nacional de Córdoba, Argentina, where she developed a deep expertise in immune system mechanisms within the tumor microenvironment. She advanced her academic journey as a postdoctoral researcher at the University of Colorado Anschutz Medical Campus, focusing on immune dysregulation in individuals with Down syndrome. Since joining BioLegend in 2023 as a Technical Applications Scientist, Paula has been a driving force in scientific innovation. Her areas of expertise include flow cytometry, single-cell genomics and proteomics, as well as molecular and cellular biology. Through her work, she provides invaluable insights and cutting-edge solutions to the scientific community.

Stephanie Pasas-Farmer is a bioanalytical expert with over 20 years of experience in pharmaceutical, biologics, and hybrid technologies. She founded BioData Solutions® in 2015 to support bioanalytical drug development through specialized consulting and software offerings. Previously, she established. Stephanie has advanced early-stage molecules into potential new drug candidates with bioanalysis support and regulatory compliance planning as well as led teams in global bioanalytical labs, focusing on large molecule and antibody-drug conjugate programs. She holds a PhD and MSc in pharmaceutical chemistry from the University of Kansas and a BS in chemistry from St. Mary's College of Notre Dame.

Mariela Bollati Fogolin is Head of the Cell Biology Unit at the Institut Pasteur de Montevideo and the Uruguayan Director of the Latin American Center for Biotechnology (CABBIO). She served as Chair of the ISAC CYTO Women Task Force from 2021 to 2024. At the Cell Biology Unit, she established a dynamic and internationally recognized facility for flow cytometry and cell culture technologies that support researchers and biotech companies across Latin America. She is widely recognized as a regional leader in biotechnology and cell biology, with a strong track record in research, teaching, and scientific leadership. Mariela holds a degree in Biochemistry and a Ph.D. in Biological Sciences from the Universidad Nacional del Litoral, Argentina. She completed her postdoctoral training at the Helmholtz Centre for Infection Research in Germany, focusing on the development of in vitro and in vivo models using flow cytometry.

Raffaello is the Global Director of Flow Cytometry at AstraZeneca, where he leads a team of 14 scientists across Washington DC, Cambridge, and Boston. His team supports over 600 scientists and 150 projects annually, aiding in the discovery and development of new therapies for various diseases. With an educational background in biotechnology and over 15 years of experience in flow cytometry, immunology, virology, and data science, Raffaello has strong expertise in both human and non-human primate models, neuroscience, and cell therapy. His work includes advancements in imaging flow cytometry and the development of new fluorochromes. He has a successful publication record with over 35 publications, a patent, and multiple certifications. In 2024, Raffaello received the ISAC Shared Research Lab Recognition Award in acknowledgment of the quality of his work. He is a passionate advocate for research excellence and pipeline delivery. His mission is to leverage his expertise and leadership to advance flow cytometry and biomedical research, contributing to the improvement of human health and well-being.

Susan Spitz, Ph.D., Incyte Corporation, Wilmington, DE Dr. Spitz is a Senior Director in the Translational Medicine department at Incyte Corporation and has over 25 years of experience in research, clinical pharmacology, and translational sciences in the pharmaceutical and biotechnology industries. At Incyte Corporation, the Translational Medicine department develops the translational strategy and executes on that strategy for preclinical and clinical studies from proof of concept and proof of mechanism through drug approval. Sue received her Ph.D. in Chemistry from Lehigh University and held positions of increasing responsibility at DuPont Pharmaceutical Company, Centocor/Janssen Biotech, and MedImmune, LLC/AstraZeneca, prior to joining Incyte in 2016. Sue has led groups that developed, validated, and executed bioanalysis for PD, biomarker, PK, and ADA assessments, performed automated methods and sample logistics, and utilized a variety of technologies in support of non-clinical and clinical programs. These efforts have contributed to the successful registration of compounds in multiple therapeutic areas. At Incyte, she contributed to building the Translational Sciences department and as a Translational Scientist has contributed to multiple small molecule and large molecule immunology, hematology, and oncology drug development programs.

Russell Weiner, PhD, FAAPS, is a recognized leader in biopharmaceuticals with over 30 years of experience in drug R&D, personalized medicine, regulated bioanalysis, and biomarker and diagnostic assay development. He is Vice President and Head of Translational Sciences at Alexion, AstraZeneca Rare Disease, leading a team focused on translational science strategies, bioanalysis, biomarker discovery and development, and diagnostics. Dr. Weiner has held senior roles at organizations such as Bristol-Myers Squibb, Merck, Daiichi Sankyo, the Bill & Melinda Gates Medical Research Institute, and Takeda, where he contributed to the development of immuno-therapeutics and oncology checkpoint inhibitors. Dr. Weiner has been actively involved with the American Association of Pharmaceutical Scientists for over 30 years and currently serves as their President. Known for his mentorship, Dr. Weiner serves as Adjunct Faculty at the University of Florida College of Pharmacy and has provided career guidance through workshops at universities worldwide.

Dr. Lili Wang is a NIST fellow and a leading expert in quantitative flow cytometry critical for diagnostics and advanced therapeutic development. She serves as the principal manager for the NIST Flow Cytometry Standards Consortium, a major Public-Private Partnership with key stakeholders from other agencies, industries, and academia, where she and her team work with consortium members to address pressing measurement and standards needed for bioassays, including SARS-CoV-2 antibody testing for diagnostics, vaccine testing, surveillance. In collaboration with WHO, her team has established multiple standards, including critical reference materials for HIV/AIDS monitoring, stem cell counting for blood transplantation, and the two international serology/antibody standards. She serves on multiple professional committees and published over 100 peer-reviewed articles. She is a recipient of the 2020 and 2021 US Department of Commerce Gold Medal. She obtained her Ph.D. in Chemistry from University of Notre Dame in 1996 and joined NIST in 1998.

Virginia Litwin is a thought-leader in validation and standardization focusing on “Cytometry from Bench-to-Bedside” . Virginia is President-Elect of ISAC and in 2023 she received the ICCS Coulter award in recognition of contributions to Clinical Cytometry. She is a member of the NIST Flow Cytometry Standards Consortium and has been an invited speaker at FDA/NIST several times.

Virginia serves on the CLSI Expert Panel and is chair for H62 and H42. She is an Editor for Cytometry Part B and has been a guest editor for special issues addressing translational cytometry. She founded the AAPS Flow Cytometry Community.

After obtaining a Ph.D. in Virology/Immunology from the University of Iowa, Virginia joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified the KIR receptor, CD158E1. She has held leadership roles in several contract research organizations. Currently she is Scientific Affairs Director at Eurofins Clinical Trial Solutions.

David Ng is an Associate Professor in the Department of Pathology at the University of Utah as well as a Medical Director of Applied Artificial Intelligence and Hematologic Flow Cytometry at ARUP Laboratories. He received his Bachelor's in Electrical Engineering from the University of Illinois at Urbana Champaign, Medical Degree from University of Illinois-Chicago, residency at Dartmouth, and fellowship at the University of Washington. He has a special interest in the development and application of machine learning to clinical flow cytometry as well as implementation of high color flow panels to diagnostic and measurable residual disease testing.

Dr. Ryan Brinkman is Vice President and Research Director of Flow Cytometry at Dotmatics Inc. and Professor Emeritus at the University of British Columbia. A pioneering figure in flow cytometry bioinformatics, he has led the development of critical data standards that have transformed the field, including latest versions of the widely-adopted Flow Cytometry Standard (FCS) file format and MIFlowCyt standards. As Chair of the Data Standards Task Force for the International Society for Advancement of Cytometry, he launched FlowRepository, the field's primary public data repository. Dr. Brinkman founded Cytapex Bioinformatics (later acquired by Dotmatics) and developed innovative automated analysis tools including flowDensity. He initiated the FlowCAP project to advance computational methods for cell population identification and has made significant contributions to ontology development in biomedical research. His work has been instrumental in improving data interoperability and reproducibility in cytometry research, earning him the ISAC Distinguished Service Award in 2018.

The research group of Oliver Otto focuses on understanding how mechanical properties of cells and tissue impact on biological function. Specifically, he is interested in the development of optical methods, microfluidic systems and tissue models to study the rheology of single cells and multicellular systems at high spatiotemporal resolution.

Oliver received his PhD in Physics from the University of Cambridge (UK). In 2012, he joined the Technical University of Dresden (Germany) as a postdoctoral researcher and in 2016 he moved to the University of Greifswald (Germany) as an independent group leader. In both assignments he worked on the development of high-throughput methods for cell mechanical characterization. Since 2021, Oliver Otto is Professor of Cellular Biophysics at the Physics Institute of the University of Greifswald (Germany).

Oliver Otto is also co-founder of the start-up company Zellmechanik Dresden, which commercializes real-time deformability cytometry, a technology for high-throughput characterization of cell mechanical properties.

Bernd Bodenmiller is a quantitative biologist specializing in the development of novel experimental and computational approaches for the quantitative analysis of tumor ecosystems. His research aims to enhance our understanding of tumor development mechanisms to advance precision oncology. Bernd earned his PhD in the group of Ruedi Aebersold at ETH Zürich and completed his postdoctoral training in the lab of Garry P. Nolan at Stanford University. In 2013, he became an assistant professor, received tenure in 2019, and was appointed as the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zurich. In 2020, he was named a Dual Professor for Quantitative Biomedicine at both UZH and ETH Zurich. He is best known for pioneering methods such as imaging mass cytometry and concepts such as cellular neighborhoods, and he has recently introduced novel multiplexed tissue imaging approaches using X-ray fluorescence.

Dr. Gibson is an associate professor in the department of Bioengineering, University of Colorado Anschutz Medical Campus with a joint appointment in the Department of Physiology and Biophysics and Neuroscience Program. She earned her Ph.D. in physics from the University of Colorado at Boulder with a specialization in nonlinear optics. Her research interest is in development of optical technologies for clinical and basic biomedical research applications. She has expertise in a variety of microscopy and spectroscopy techniques for measurement of biological samples from protein, cellular to in vivo models. Her lab is involved in collaborations with neuroscientists and neurosurgeons to design optical imaging tools to allow new studies of the brain.

Dr. Ihrie completed undergraduate studies in Biochemistry with Honors at the University of Michigan, a Ph.D. in Cancer Biology at Stanford University with Dr. Laura Attardi, and postdoctoral studies at UCSF with Dr. Arturo Álvarez-Buylla. Her work has been recognized by the Damon Runyon Cancer Research Foundation, the American Association for Cancer Research/National Brain Tumor Society, the Southeastern Brain Tumor Foundation, and the Ben & Catherine Ivy Foundation for Brain Tumor Research. Since 2012, the Ihrie Lab has studied signaling and fate decisions in the stem cells of the brain and stem-like cells in brain tumors using high dimensional cytometry. Recently, the lab and collaborators developed a new imaging analysis workflow to classify cellular neighborhoods across patient brain tissue specimens. In 2024, the Ihrie lab moved from Vanderbilt University to the University of Colorado. Dr. Ihrie is a Professor in Pediatrics - Section of Child Neurology at CU Anschutz.

Elena Hsieh earned her MD degree from University of California San Francisco (UCSF) in 2008. She completed a residency in pediatrics at the University of California Los Angeles (UCLA) in 2011, and a fellowship in Allergy and Immunology at Stanford University in 2014. During her fellowship she worked in Dr. Garry Nolan's laboratory studying pediatric lupus. She continued her research and clinical work at Stanford University as an Instructor for an additional year. In 2015, she joined the faculty at the University of Colorado School of Medicine, jointly affiliated with the Children's Hospital of Colorado. She is currently an Associate Professor of the Department of Immunology and Microbiology, and Pediatrics, Section of Allergy and Immunology. She is the Director of the Jeffrey Modell Center for Primary Immunodeficiency, and co-directs the Severe Combined Immunodeficiency Newborn Screen Program, both of which constitute the foundation of the immunodeficiency program at Children's Hospital Colorado. She is also the director of University of Colorado as a FOCIS Center of Excellence. The Hsieh lab addresses mechanistic and translational questions in human immunology to enable a deeper understanding of normal immune function, and dysregulated immune processes in immunodeficiency, autoimmunity, and the overlap between the two. Her lab focuses on classical pediatric autoimmune disorders such as lupus, multiple sclerosis, and type 1 diabetes, as well as genetic immune dysregulation disorders. Her lab has identified several novel human inborn errors of immunity (IEI) that lead to severe multi-organ autoimmunity/autoinflammation and infectious susceptibility. Her lab has developed mouse models from homologous human mutations to further enlighten underlying disease mechanism. Dr. Hsieh expanded her studies of immune dysregulation to Down Syndrome and COVID-19 disease given the type I interferon hypersensitivity observed in these disorders. Elena joined JEM as Associate Editor in 2023.

Maria Elena Bottazzi is a distinguished scientist and a leading figure in the fields of vaccinology and neglected tropical diseases. With a career spanning over two decades, Dr. Bottazzi has made remarkable contributions to global health through her research, leadership, and advocacy efforts. She is Professor of Pediatrics and Molecular Virology and Microbiology, currently serving as the Sr. Associate Dean of the National School of Tropical Medicine and Division Chief of Pediatric Tropical Medicine at Baylor College of Medicine. She is also the Co-director of Texas Children's Hospital Center for Vaccine Development, where Dr. Bottazzi has been instrumental in advancing innovative approaches to combat diseases that disproportionately affect underserved populations worldwide. Her work focuses on developing vaccines and therapeutics for neglected tropical diseases such as hookworm, schistosomiasis, Chagas disease, and tick-borne diseases. Dr. Bottazzi is widely recognized for her pivotal role in the co-development of an open science vaccine technology against COVID-19 that led to the development of Corbevax in India and IndoVac in Indonesia, and with approximately 100 million doses delivered. Throughout her career, Dr. Bottazzi has been a vocal advocate for equitable access to healthcare and vaccines, particularly for marginalized communities in low- and middle-income countries. She has collaborated with international organizations, governments, and non-profits to promote initiatives aimed at addressing health disparities and improving global health outcomes. Dr. Bottazzi is a member of the US National Academy of Medicine (NAM), a Leshner Leadership Institute Public Engagement Fellow in Infectious Diseases of the American Association for the Advancement of Science and an Executive Leadership in Academic Medicine (ELAM) alumna. Dr. Bottazzi's dedication to scientific research, combined with her commitment to social responsibility, has earned her numerous accolades and honors. In 2023, she was awarded the Vilcek-Gold Award for Humanism in Healthcare and the Rachael Schneerson - John Robbins Prize. For three years in a row, Forbes selected Dr. Bottazzi as one of 100 Most Powerful Women in Central America and in 2022, alongside Dr. Peter Hotez, she was nominated by Texas Congresswoman Lizzie Fletcher for the Nobel Peace Prize. She continues to inspire future generations of scientists through her mentorship and educational outreach efforts, fostering a legacy of excellence in the pursuit of improving health and well-being for all. Dr. Bottazzi obtained her bachelor's degree in microbiology and clinical chemistry from the National Autonomous University of Honduras and a doctorate in Molecular Immunology and Experimental Pathology from the University of Florida. Her post-doctoral training in Cellular Biology was completed at University of Miami and Pennsylvania, where afterwards worked at the George Washington University prior to relocating to Texas.